Chinese biotechnology company Ascletis Pharma Inc (HKEX:1672) on Monday reported positive results from a randomised, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in the United States.
This Phase I study was designed to evaluate the safety, efficacy and pharmacokinetics of once-daily 200 mg of ASC50 after 28-day treatment in mild-to-moderate plaque psoriasis patients.
According to Ascletis, findings showed a placebo-adjusted reduction of 48.9% in psoriasis area and severity index (PASI) score in mild-to-moderate plaque psoriasis patients after once-daily 200 mg 28-day treatment. Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing.
The placebo-adjusted reduction in PASI score increased to 60.7% and 65.9% 6 days and 15 days, respectively, after the last dose (28th dose). These data also support potential once-weekly oral dosing.
Once-daily 200 mg dosing demonstrated comparable reduction in PASI score to published data on secukinumab, the marketed interleukin-17A (IL-17A) antibody drug.
The data showed strong target engagement after 28-day dosing, indicated by elevated plasma IL-17A levels.
Additionally, once-daily 200 mg 28-day treatment was safe and well tolerated, with no serious adverse events reported and no discontinuation in the study. No alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations were observed, and no hepatic safety signal was detected.
ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting IL-17A, an important biologically and commercially validated target for multiple autoimmune and inflammatory diseases, including psoriasis. ASC50 is a new chemical entity (NCE) with a novel scaffold.
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product